What is the best drug-delivery approach for the acute treatment of migraine?

Click to increase image sizeClick to decrease image size

Financial & competing interests disclosure

SJ Tepper is a consultant, or on the scientific advisory board or speaker’s bureau, for: Allergan, GSK, Helsinn, MAP, Merck, Nautilus, NuPathe and Zogenix. He has received research grants from ATI, Allergan, BristolMyerSquibb, GSK, MAP, Merck, NuPathe and Zogenix (no personal compensation). MJ Stillman is on the speaker’s bureaus for GlaxoSmithKline, Pfizer and Merck pharmaceutical companies. He has received consulting fees from Capnea Inc. MJ Stillman and members of his center, the Cleveland Clinic Headache Center, received financial support for research activities from the following pharmaceutical companies: ATI, Allergan, Bristol-Myers Squibb, GSK, MAP, Merck, NuPathe and Zogenix (no personal compensation). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.